Mesenchymal Stem Cells
Mesenchymal Stem Cells (MSCs) have shown effectiveness in the area of regenerative medicine with multiple treatments hitting the market in the last decade to help restore tissue damage in bones, cartilage, and other areas. MSC therapy is also being developed to treat acute graft-versus-host-disease and recently, the cells have shown promising effects to treat severely damaged lung tissue caused by COVID-19. With MSC treatments being pursued in various high-impact disease areas, scalability while maintaining efficacy to support large volumes of patients continues to be a challenge. The Catalent team has partnered with clients to address complexities with scalability and have brought allogeneic MSC treatments to the clinical manufacturing phase with well-established processes that transition into commercial readiness.